Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1
JCEM Case Reports · 20.05.2026 · 4 (7)
DOI: 10.1210/jcemcr/luag112 ↗Kurz gefasst
Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 09.06.2026. Verfasst von Alexandra Lim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NIAID NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Immune checkpoint inhibitor (ICI) cancer therapies targeting programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 enhance antitumor immunity in many cancers. Despite its efficacy, ICI therapy can trigger severe autoimmune attacks across various organ systems, termed immune-related adverse events (irAEs). Antitumor immunity and autoimmunity are tightly linked as demonstrated by the enhanced efficacy of ICI therapy in patients who develop irAEs. Whether patients with preexisting autoimmunity or genetic risk factors for autoimmunity should be offered ICI therapies remains uncertain. We present the case of a patient with autoimmune polyglandular syndrome type 1, caused by a pathogenic autoimmune regulator (AIRE) missense mutation, who was treated with ICI therapy for squamous cell carcinoma of the hard palate. She subsequently developed 3 concurrent irAEs: ICI-hepatitis, ICI-thyroiditis, and ICI-diabetes mellitus. For these irAEs, the patient was treated with immunosuppressants, thyroid hormone replacement, and basal bolus insulin therapy. This case highlights the need for careful evaluation of patients for underlying autoimmune diseases prior to ICI therapy initiation. It also highlights a 2-hit model wherein any impaired central immune tolerance combined with ICI therapy may predispose patients to multiple severe irAEs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.
- UCLA/California Institute of Technology Medical Scientist Training Program, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.
- Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.
- Division of Transplant Hepatology, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.
- Division of Hematology Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.
- Division of Endocrinology, Greater Los Angeles Veterans Affairs Healthcare, Los Angeles, CA 90073, USA.
ORCID-Profile: Esther M Peluso, Brian H Horwich, Melissa G Lechner
Förderung
- NIDDK NIH HHS
- NIAID NIH HHS
- National Institutes of Health
- Aramont Charitable Foundation
- Doris Duke Foundation
Zitieren
APA
Lim, A., Peluso, E. M., Downs, I. A., Horwich, B. H., Velez-Velez, M. A., & Lechner, M. G. (2026). Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1. JCEM Case Reports, 4(7). https://doi.org/10.1210/jcemcr/luag112
Vancouver
Lim A, Peluso EM, Downs IA, Horwich BH, Velez-Velez MA, Lechner MG. Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1. JCEM Case Reports. 2026;4(7). doi:10.1210/jcemcr/luag112
BibTeX
@article{Lim2026,
author = {Lim, Alexandra and Peluso, Esther M and Downs, Ian A and Horwich, Brian H and Velez-Velez, Maria A and Lechner, Melissa G},
title = {Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1},
journal = {JCEM Case Reports},
year = {2026},
volume = {4},
number = {7},
doi = {10.1210/jcemcr/luag112}
}
EUVIMED